Functionalization and Cellular Uptake of Boron Carbide Nanoparticles. The First Step toward T Cell-Guided Boron Neutron Capture Therapy

2006 ◽  
Vol 17 (2) ◽  
pp. 284-290 ◽  
Author(s):  
M. W. Mortensen ◽  
O. Björkdahl ◽  
P. G. Sørensen ◽  
T. Hansen ◽  
M. R. Jensen ◽  
...  
Keyword(s):  
T Cell ◽  
Boron Carbide ◽  
Cellular Uptake ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

Towards improved boron neutron capture therapy agents: evaluation of in vitro cellular uptake of a glutamine-functionalized carborane

2009 ◽  
Vol 14 (6) ◽  
pp. 883-890 ◽  
Author(s):  
Antonella Crivello ◽  
Carlo Nervi ◽  
Roberto Gobetto ◽  
Simonetta Geninatti Crich ◽  
Iboya Szabo ◽  
...  
Keyword(s):  
Cellular Uptake ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

Cellular uptake evaluation of pentagamaboronon-0 (PGB-0) for boron neutron capture therapy (BNCT) against breast cancer cells

2019 ◽  
Vol 37 (6) ◽  
pp. 1292-1299
Author(s):  
Adam Hermawan ◽  
Ratna Asmah Susidarti ◽  
Ratna Dwi Ramadani ◽  
Lailatul Qodria ◽  
Rohmad Yudi Utomo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cellular Uptake ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Breast Cancer Cells ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

scholarly journals Boron-Rich Boron Carbide Nanoparticles as a Carrier in Boron Neutron Capture Therapy: Their Influence on Tumor and Immune Phagocytic Cells

Materials ◽  
2021 ◽  
Vol 14 (11) ◽  
pp. 3010
Author(s):  
Dawid Kozień ◽  
Bożena Szermer-Olearnik ◽  
Andrzej Rapak ◽  
Agnieszka Szczygieł ◽  
Natalia Anger-Góra ◽  
...  
Keyword(s):  
Boron Carbide ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Average Particle Size ◽  
Average Particle ◽  
Neutron Capture Therapy ◽  
Direct Reaction ◽  
Phagocytic Cells ◽  
Boron Neutron Capture ◽  
Human Immunoglobulins

The aim of the work was to study the interaction between boron-rich boron carbide nanoparticles and selected tumor and immune phagocytic cells. Experiments were performed to investigate the feasibility of the application of boron carbide nanoparticles as a boron carrier in boron neutron capture therapy. Boron carbide powder was prepared by the direct reaction between boron and soot using the transport of reagents through the gas phase. The powder was ground, and a population of nanoparticles with an average particle size about 80 nm was selected by centrifugation. The aqueous suspension of the nanoparticles was functionalized with human immunoglobulins or FITC-labeled human immunoglobulins and was then added to the MC38 murine colon carcinoma and to the RAW 264.7 cell line of mouse macrophages. Flow cytometry analysis was used to determine interactions between the functionalized boron carbide nanoparticles and respective cells. It was shown that B4C–IgG nanoconjugates may bind to phagocytic cells to be internalized by them, at least partially, whereas such nanoconjugates can only slightly interact with molecules on the cancer cells’ surface.

Sign in / Sign up

Export Citation Format

Share Document